Yeah, like you didn't see this fundraising coming with a major dilution to go with it. They had no cash. Until there is real data this is going much lower.
Terry, I think that this is pSivida's year end ,June 30th. So, we won't report until Sept. It will however be very
interesting to catch Dan Myers on the ALIM call coming up.
In spite of a lack of a J code this year, I bet Iluvien sales are on the rise. It would be nice to
see the EU pick up with Portugal and the UK. France as always is screwed and will continue to be
because, well....it France. When is Australia and New Zealand coming on line with distribution?
A share of the annual Uveitis market share of 175K patients is not a small market. It's a billion dollar market. And, if you've been developing and refining the best delivery system, that lasts for three years and just might prove to be the best therapy for the indication, wouldn't that be worth more than 120Mil MC? The answer is yes. A "TEN" percent share of the market, where there is no drug (other than pSivida's other FDA approved product for the indication) , would be 17.5K @ 8K......well that's $140M annually. This indication alone puts us at 850M MC. Patience all. The first PIII data is March. The FDA might be a bit forgiving with "Kick As*" data on an early approval. And I think the last investigator sponsored "DUKE DATA", kicks but. The trial study that is ongoing may not be curing blindness.....only because that particular patient would not be allowed in the trial. Hang in there guys. This company will rock. Paul Ashton will prove himself on Medidur alone....Uveitis will generate a lot of money......for any acquiring company. Shhhhhh. that doesn't include any interest for the pipeline.
One addition piece of food for thought here; Pfizer recently filed with the SEC, their statement of ownership in pSivida. That hasn't been done in all the years that I've had a position in the company. It was just a restatement of what they owned. I think it was Terry that brought it to light on the MB. Peculiar I'd say. What does it mean? Who knows, but it was a bit odd. I ran that by Beverly....she said she had not seen it restated by Pfizer either , in a very long time. pSivida is caught in a catch 22 here. Our MC is so low, most institutions are prohibited from owning it. Then, our liquidity is so low by our low volume that we not an attractive company to take a position in on the open market, or it would just drive up the price. Then, institutions can't take a position in a secondary because we trade in the Australian market. By rule we can not dilute more than 15% a year. So, we sit at these levels until data drives us higher, then perhaps something good happens. During this whole time we are vulnerable to being pushed up and down on low volume trading. It's all good. Someday we'll get noticed for all the right reasons
Terry, Pfizer splitting into two segments makes sense. Tom brought that up in a post not too far back on this MB. This is where patience as a pSivida shareholder is paramount. "If" pSivida really has the goods to deliver biologics then it is a very worthwhile pursuit for any big pharma. At the same time any acquiring pharma would be getting the Durasert/Medidur platform on the cheap as well. At 120M MC, pSivida is just too undervalued. If it's about data then I'm sure Paul Ashton is doing his best here. Data is everything. Ask the CEO of Avalanche...oh, he resigned.
Nord, I believe in Iluvien. I didn't years ago as it created a portion of patients that had an increase in IOP. It does however seem it is the most cost effective drug for DME. If the patient is not elevated IOP sensitive, the Iluvien insert will be the drug of choice. If you're a
government trying to save vision and money , this is the way. We are probably 3 more quarters of making US revenue for PSDV, but this quarter for ALIM will give guidance going forward into the next......etc. Either way progress is being made slow and steady.
What a treat for Paul really. Tiny company like pSivida and it's CEO presenting his concept of minimal drug exposure , site specifically delivered over time (years potentially). Durasert and Medidur has huge data to back up efficacy now (Uveitis and DME) . Other small molecules could be finding their way into the clinic soon.....let's hope. After all, small molecule drugs seem to be delivered effectively on a yearly basis. Now it's time to see big pharma jumping in to the clinic with pSivida. Ozurdex doesn't provide the long term platform. That leaves pSivida at 120Mil MC. Go figure
With Xoma's recent PIII letdown it seems it's kind of the "last man standing" thing. Even I'm surprised that the
companies focused on eye disease and drug development have taken of few hits of late. Yet for all these years pSivida has had an FDA approved sustained release platform that they've slowly and steadily improved. Think about Iluvien, it's gaining in recognition with every day that passes, albeit at the expense of drug companies and other drug delivery companies unfortunate failures. Back of the eye drugs and "devises" isn't easy baby. Ask the developers of Allergan's Ozurdex; they're getting 3 months therapy out of it.....hoping for 4.....advertised as 6. Medidur data in March will be big don't you think? By then the other's evaluating Durasert will be taking notice. Tethadur.......what's that?
The best point of all , I might add. Our data is looking better than ever. Not to mention the
data being generated in the new small molecule gig on the evaluation agreements. I think Ashton is
going to show some capability here with the Durasert platform; just sayin'. Looks like we'll all be here either way.
JD, Think of the MC of all the companies you've mentioned. Seems like pSivida is the only company not getting any respect, by virtue of it's tiny MC. Something isn't right about that. Why little interest by analysts and institutions still puzzling. The math is pretty straight forward when you factor just Medidur and a three year release on many small molecules. We need a Dry Eye NDA, HSS gig with a major partner that pays the way and some Tethadur news.......any Tethadur news. EYEG is up 24% today with no data on anything, ever.
As a percentage, we all own a good piece of this company. I'll be honest, I thought Tethadur data would be forthcoming before now. It has not materialized. It is however worthy of taking note that pSivida is working with Big Pharma companies, as always . The subtleties of deal making is out of our view. What we do have however is real substantive data regarding their approved platform. Even this data is not factored into today's SP. Someday it will be , and I'll be here to report on this MB that I saw it coming. Either way, I'm watching with the rest of you.
Yeah, just watching ELON has taught me that I'm glad I pulled the sell trigger at 2.50......Seems I only lost a couple of grand. But, I come back here to read the profound posts and resulting insight I get from reading them. You taught me DCA. I feel that I'm all grown up now ......just because of it . Thank you.
Deeply disturbed too. But I love coming to this MB just to catch up on things. You are a lucky guy.
I couldn't put it better myself. If EYEG has content it will show itself by continuing it's upward movement. How could the shorts sleep at night with that one. We could be wrong, but if we are it will take years to prove us wrong. I still like the valuations of pSivida. I do wish we were higher in SP. We too have to prove our value with data and or license deals. We are in serious need of license deals if we do in fact have a viable platform technology, they can't be that far away.